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The connected past and future 
of transplantation, with particular 
emphasis on the liver 
T. E. STARZL 
INTRODUCTION 
Every major advance in liver and other kinds of organ transplantation of the last 
half century has required the overthrow of some scientific dogma or the revision 
of a social, ethical, or legal doctrine. Consequently, the growth of transplantation 
was more a 50-year war against the status quo than an orderly evolution. The 
war can be divided into five distinct phases. Although my main focus will be on 
phase 4, it is essential to understand what happened from the beginning. 
PHASE 1 
The spark that ignited the war was the demonstration in 1953 by Billingham, 
Brent, and Medawar that immunologically immature neonatal mice or irradiated 
adult mice whose bone marrow had been 'replaced' by the haematolymphopoi-
etic cells of an adult donor (donor leucocyte chimerism) could accept skin from 
the cell donor strain but from no other strain1,2. This was the first example of 
acquired transplantation tolerance. The next step appeared to be obvious; i.e. 
bone marrow transplantation from the donor before or at the same time as the 
organ transplantation. The hazard of this strategy was recognized by Medawar's 
associates, Billingham and Brent3A and by Simonsens, who discovered that the 
engrafted donor immune cells could tum the tables and reject the mouse recipi-
ents (graft-versus-host disease). This complication was avoidable only with a 
good donor-recipient tissue match. 
This work established the association of alloengraftment of tissues (and sub-
sequently organs) with donor leucocyte chimerism. Shortly afterwards, and to 
the surprise of most immunologists, successful kidney transplantation without 
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infusion of donor leucocytes (i.e. in the ostensible absence of leucocyte 
chimerism) was accomplished six times between January 1959 and February 
19626-10 (Table 1). All six patients had been conditioned before transplantation 
with sublethal total-body irradiation. Such trials would not be possible today. 
Until well into 1960, prolonged survival had never been achieved in an animal 
after kidney transplantation with any kind of treatment. Nevertheless, surgeons 
had forged ahead with clinical kidney transplantation, and with the development 
of experimental models of transplantation of all other major organs. My own 
interest had turned to the liver. By 1960 the operation of liver replacement in 
dogs had been perfected in our laboratory 1 1.12 and in BostonI3.1 4. 
Without the availability of immunosuppression such efforts were made, at first, 
in a vacuum. However, a sea change began in 1960 with the demonstration that 
the survival of rabbit skin allografts 15•16 and of canine kidney allografts17- 19 was 
prolonged by treatment with the drug 6-mercaptopurine and its imidizole deriva-
tive, azathioprine (better known as Imuran®). The drugs also were tested in canine 
liver recipients2o. Although survival of the canine kidney recipients for as long as 
100 days was limited to 5% or less, this did little to dampen the initial burst of 
enthusiasm. The enthusiasm evaporated when all but one of the first 13 kidney 
recipients treated with the new drugs in the Boston I 0 and London clinical trials21 
died in less than 6 months. The only ray of hope lay with Murray's single surviv-
ing patient - the recipient of a kidney from a non-related donor on 5 April 196210• 
This kidney in Murray's patient functioned for 17 months, adding a seventh 
human to the I-year kidney transplant survival list - and for the first time, with-
out total body irradiation (Table 1, below the dashed line); it was a landmark 
case, but because of the otherwise dismal results, we concluded that we would 
have to develop kidney transplantation from the ground up before contemplating 
our primary goal of liver transplantation. During the summer of 1962 we made 
three reproducible new observations in canine kidney recipients. A few months 
later these were confirmed in human recipients22• First, kidney rejection in dogs 
that developed under Imuran could almost always be reversed by adding large 
doses of prednisone23. Second, mean survival was nearly doubled by pretreating 
the animals with lmuran for 1-4 weeks instead of beginning the drug at the time 
of transplantation24. The third and most important observation was the develop-
ment of what we considered to be variable donor-specific tolerance. Tolerance 
Table 1 Kidney transplantation :=:6 months survival as of March 1963 
Cil .... fre! Dale DOllar Sun'ivai (months) 
1. Boston" 24 January 1959 Fraternal twin >50 
2. Paris7 29 June 1959 Fraternal twin >45 
3. Paris9 22 June 1960 Unrelated" 18 (died) 
4. ParisH 19 December 1960 Mother 
, 
>12 (died) 
5. Paris9 12 March 1961 Unrelated' 18 (died) 
6. ParisH 12 February 1962 Cousin' >13 
7. Boston II) 5 April 1962 Unrelated 11 
" Adjunct steroid therapy. 
Boston: J. E. MUiTaY (I and 7): Paris: J. Hamburger (2. 4 and 6): R. Kuss (3 and 5). 
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Recipient LJlmmunosuppresslon • No Immunosuppression Donor CR 
1 .------------------._ Sister <1.5 
2 Brother <1.5 
3 _ Mother <1.5 
4 • Mother <1.5 
5 I Mother 2.5-3 
6 
7 
8 
9 
o 10 
I 
20 30 
Years Post Transplantation 
40 
<1.5 
<1.5 
Figure 1 Nine (19%) of the 46 live-donor kidney recipients treated at the University of Colorado 
over an IS-month period beginning in the autumn of 1962. The solid portion of the horizontal bars 
depicts the time off immuno:;uppression. Note that the current serum creatinine concentration (CR) is 
normal in all but one patient. * Murdered: kidney allograft normal at autopsy 
was inferred from the declining need for immunosuppression after the successful 
reversal of rejection. 
These observations in humans, and our interpretation of the findings, were sum-
marized in the title of a report in the October, 1963 issue of Surgery, Gynecology & 
Obstetrics22. Our use of the word 'tolerance', was severely criticized at the time; but 
it proved to be the correct term. The nine horizontal bars in Figure 1 represent nine 
patients (or 19%) of those given live-related kidneys in Denver from the autumn of 
1962 to December 1963. The nine allografts functioned for the next four 
decades25•26. The important point is that seven of the nine recipients stopped all 
drugs without suffering rejection, for periods ranging from 3 to 39 years (the black 
portion of the horizontal bars). One of the rune patients was recently murdered, and 
had a normal kidney at autopsy. The eight who remain bear the longest surviving 
kidney allografts in the world today, 40 or more years post-transplantation. 
Although the follow-ups of the kidney recipients were still short, this promis-
ing experience with renal transplantation triggered the decision to begin a liver 
trial on I March 1963. The first patient was an unconscious and ventilator-bound 
child with biliary atresia. The child bled to death during the operation27 . Four 
more attempts were made in Denver later in 196320.27 - as well as one each in 
80ston28 and Paris29 . Although five of the last six patients survived operation, 
they all died after 6-22 days (Table 2). With these successive failures by the end 
of 1963 all liver transplant activity ceased worldwide for the next 3j- years. 
The decision to stop was voluntary; it was reinforced. however, by widespread 
criticism of replacement of an unpaired vital organ with an operation that had 
come to be perceived as too difficult ever to be tried again by a responsible sur-
geon. In contrast. kidney transplantation, whose development in Denver was only a 
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Table 2 First seven recipients of livers 
Age Date Cirvlref Liver SlIrl'il'll/ Main calise 
(wars) disease (davs) ofdearh 
3 I March 1963 Denver27 Biliary 0 Intra-operative 
atresia bleeding 
48 5 May 1963 Denver27 Hepatoma, 22 Pulmonary 
cirrhosis emboli, sepsis 
68 3 June 1963 Denver27 Duct cell 7.5 Pulmonary 
carcinoma emboli 
52 10 July 1963 Denver20 Hepatoma, 6.5 Gastrointestinal 
cirrhosis bleed, pulmonary 
emboli 
58' 16 September 1963 BosLOn28 Colon II Sepsis, liver failure 
metastases 
29 4 October 1963 Denver20 Hepatoma 23 Sepsis, pulmonary 
emboli 
75 t 1 January 1964 Paris29 Colon 0 Haemorrhage 
metastases 
, Boston; t Paris. 
preliminary step to the main goal of liver transplantation, seized centre stage. This 
fIrst textbook on renal transplantation, published in 1964, was based on our fIrst 70 
cases30. In contrast, liver transplantation had become a ticket to academic suicide. 
During the 3t-year liver moratorium three advances were made that were 
applicable to all organs. First, we showed, in a collaboration with Paul Terasaki of 
UCLA, that HLA matching had little association with kidney transplant outcome 
unless the match was perfect31 - 33 . By inference, desperately ill liver, heart and 
other transplant candidates who could not wait for a well-matched organ would 
not suffer a major penalty by receiving a mismatched one. For those committed to 
HLA matching, however, these conclusions were not welcome. The guerilla war 
that followed was not resolved until the 1990s, when it could fInally be under-
stood why HLA matching was a prerequisite for bone-marrow transplantation. 
but was not essential for organ transplantation (see later). 
The second objective was to -improve immunosuppression. Antilymphocyte 
globulin (ALG) was prepared from the serum of horses immunized against lym-
phoid tissues. The ALG was tested in do~s and introduced clinically in 1966 in 
combination with Imuran and prednisone' 4. ALG, and the following generations 
of monoclonal antibody analogues. remain an important part of our treatment to-
day. The studies in dogs during the moratorium resulted in many long-surviving 
recipients. The liver was the hardest organ to transplant. but it appeared to 
induce dmg-free tolerance more readily than the kidney or any other organ. Most 
of these animals, including one that lived for 13 years, were treated only with a 
short course of Imuran35, or a few doses of perioperative ALG34; but no-one was 
willing to consider these animals to be tolerant. Like our tolerant human kidney 
recipients the dogs ostensibly did not have the donor leucocyte chimerism of 
Medawar's acquired tolerance. 
As our third objective we developed a sophisticated perfusion system in 1966 
and 1967 that permitted the reliable preservation of canine livers for as long as 
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a day after their removal·,6. Now it was time to try again. After the clinical liver 
programme was reopened, in July 1967, several examples of prolonged human 
liver recipient survival were produced under triple-drug immunosuppression 
with Imuran, prednisone. and ALG37• Although less than half of the liver trans-
plantations of 1967 resulted in prolonged survival, the successes had a domino 
effect. Between January 1968 and November 1969 the tirst long-surviving 
human heart38, pancreas39, and lung40 recipients were produced in Capetown, 
Minneapolis, and Louvain all under the triple-drug immunosuppression devel-
oped in Denver for kidney and liver transplantation. In addition, the first success-
ful bone-marrow transplantations were finally accomplished in 196841 (Table 3). 
Table 3 First successful transplantation of human allografts (survival> I year) 
Organ City/ref Date Physician/wrgeoll 
Kidney Boston6 24 January 1959 MerrilllMurray 
Liver Denver'7 23 July 1-967 Starzl 
Heart Cape Town38 2 January 1968 Barnard 
Bone marrow Minneapolis41 25 August 1968 Gatti 
Solid Organ Bone Marrow 
Non-es.enll.'·_-tC...Ir .. t....-- Tlesue Match KKKKK:~~1f1t~i Essential 
~cceptKnce __ ~--~~f------ Gr.aft rake -------4-f!K~f----;_ Tolerance 
Uncommon -f--R--:'I'I!D------- GVHD 
lMedawar) 
Figure 2 The divergence of the ostensibly unrelated fields of organ (left) and bone-marrow trans~ 
plantation. The conclusion that the two kinds of transplantation involved different mechanisms ot 
engraftment was the basis for an epistemological collapse in transplantation immunology (see text) 
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Thus a beach-head of clinical transplantation had been established by 1969, 
spearheaded by the kidney and liver. This concluded the 16-year phase 1 of the 
50-year war. By now, bone marrow and organ transplantation had parted com-
pany (Figure 2). Drug-free tolerance that was clearly associated with donor leu-
cocyte chimerism was a clinical reality after bone-marrow transplantation, but 
only with the use of HLA-matched donors. In contrast, it had become unchal-
lenged dogma that organ recipients did not have such chimerism, implying that 
organ engraftment involved separate and different mechanisms. Acceptance of 
this misconception became the dark legacy of phase 1. It was a pervasive error 
that permeated all levels of transplantation immunology, and immunology in 
general, for the next third of a century. 
PHASE 2 
Although the mechanisms of alloengraftment were enigmatic, and would remain 
so for the next quarter-century, the early successes were construed as a break-
through; however, the jubilation was short-lived. The succeeding phase 2 was a 
bleak period that lasted for a dozen years. In the view of critics the heavy mor-
tality, and particularly the devastating morbidity, caused by steroid dependence, 
made organ transplantation (even of kidneys) more a disease than a treatment. 
By 1979 the liver programme in Denver and the heart transplant programme of 
Norman Shumway at Stanford were the only ones of their kind in America. The 
climate was better in Europe. Swimming against the stream, Roy Caine, Rudolf 
Pichlmayr, Henri Bismuth, and Rudi Krom kept the liver transplant flame alive 
in Cambridge, Hanover, Paris, and Leiden. All the while, surviving recipients in 
these programmes bore silent witness to what some day would be accomplished 
on a grand scale. A woman, who today is the world record-holder for a non-renal 
organ, was 4 years old when her liver was replaced in Denver for biliary atresia 
and a hepatoma in January 1970. Now, more than a third of a century later, she 
and many other liver recipients close behind have stopped their immunosuppres-
sion without rejecting25 . . 
PHASE 3 
What had appeared to be the end of a shattered dream was only the dawn of 
phase 3 of the 50-year war. Phase 3 began with the clinical introduction of the 
new drug, cyclosporin, by Caine in England42 and its combination with pred-
nisone in Denver and Pittsburgh43,44. A decade later cyclosporin was replaced by 
tacrolimus in Pittsburgh45.46 and eventually elsewhere. The new drugs improved 
the outlook for all organs, but the stepwise impact was most conclusively 
demonstrated with liver transplantation (Figure 3). Moreover, it became possible 
with tacrolimus to develop transplantation of the intestine47 (a previously for-
bidden organ). In 1990 the first successful pancreatic islet transplantations in the 
world were carried out in Pittsburgh48. By the end of the 20th century all of the 
major organs except the brain were being transplanted in every developed coun-
try in the world. 
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Figure 3 Patient survival: the three eras of orthotopic liver transplantation at the Universities of 
Colorado (1963-1980) and Pittsburgh (1981-1993), defined by azathioprine (AZA)-, cyclosporin 
(CYA)-, and tacrolimus (TAC)-based immune suppression. Stepwise improvements associated with 
the advent of these drugs were also made with other kinds of organs 
PHASE 4 
There were, however, nagging disappointments. The inherent risks of immune 
depression and drug-specific side-effects precluded a normal life expectancy. 
Moreover, the sporadic examples of drug-free tolerance observed earlier with 
less potent immunosuppression were expected to be more common. Instead, they 
were almost never seen again. It was obvious that further advances would 
require elucidation of the enigmatic mechanisms of alloengraftment and toler-
ance. In 1992 we obtained evidence that bone-marrow and organ engraftment 
involved the same immunological mechanisms, and were merely variations on 
the same theme49- 54. This conclusion was reached when donor leucocyte 
chimerism was demonstrated in 30 kidney or liver recipients surviving from 
phases 1 and 2 who had borne functioning grafts for up to three decades. Using 
sensitive immunocytochemical and/or peR techniques, donor leucocytes were 
detected in one or more of the recipient tissues depicted in Figure 4 (or in the 
blood) of all 30 patients. Because the cells were sparse their presence was 
termed 'microchimerism'. The presence of microchimerism in these patients sig-
nalled a paradigm shift in transplantation that precipitated and defined phase 4 of 
the 50-year war. 
Until this time the events set in motion by transplantation had been largely 
viewed in the context of an all-or-none immune response, exemplified by the 
host-versus-graft response that normally proceeds to rejection of the transplanted 
organ (Figure 5, panel A). After bone-marrow transplantation the recipient either 
completely rejected the graft or, as shown in panel B, the transplanted bone mar-
row completely replaced that of the recipient and could reject the recipient 
(graft-versus-host disease). The dogma depicted in panels A and B was incom-
patible with our microchimerism discoveries, or with the demonstration by 
Donna Przepiorka et al. of Seattle55 that cytoablated bone-marrow recipients 
always had a small residual popUlation of their own bone-marrow-derived cells. 
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'* Heart ... ;:.:,.---!-----
1:1 Liver 
~--n==n Blood '* 
'* Bone marrow .',. "I""-+~oK 
Figure 4 Host sites sampled in studies in 1992 of the longest-surviving kidney and liver recipients 
in the world, Donor leucocytes were looked for in host blood, skin, and lymph nodes, as well as in 
the allograft (here liver) of all patients, and in selected cases biopsies were also taken from the heart, 
intestine, other organs, or bone marrow. The concepts depicted in Figures 5 and 7 were deduced from 
the finding of low-level donor leucocyte chimerism in all patients, and confirmed in a series of 
controlled animal experiments 
Instead, it was obvious that organ engraftment (Figure 5, panel C) and bone-
marrow engraftment (panel D) were mirror images, and that both kinds of recipi-
ent had donor leucocyte chimerism. 
It now could be deduced that alloengraftment after both procedures resulted 
from 'responses of coexisting doOor and recipient cells, each to the other, caus-
ing reciprocal clonal exhaustion, followed by peripheral clonal deletion'49.51. 
The passenger leucocytes of a transplanted organ are of bone-marrow origin and 
include stem cells. Consequently, their haematogenous spread into the recipient 
was the same as that following a bone-marrow cell infusion. The migration is 
selective at first to the host lymphoid organs, where the donor cells induce an 
anti-donor T-cell response. Donor cells that escape destruction begin to spread to 
ubiquitous non-lymphoid sites after about 30 days. 
In clinical practice, and in most experimental models, clonal exhaustion-
deletion requires a protective umbrella of immunosuppression to prevent the 
recipient cell population from destroying the donor leucocytes before deletion 
can occur. In some experimental models, however, the exhaustion-deletion 
occurs without treatment (summarized in refs 25 and 26). The usual allograft in 
these spontaneous tolerance models is the liver, with its large quantity of passenger 
leucocytes. 
Exhaustion and deletion of the dominant response of organ transplantation in 
the spontaneous tolerance models, or under an umbrella of immunosuppression 
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A. Single Response (organ) 
P roIiIe1ation 
of hoot 
anliilfOllt ceHs 
HVG (,ejectlon) __ '" 
C. Double Response (organ) 
Immunosuppression 
GVH -----. I o~~ag ~ I ~ .. :t:. ~1DcRD Ai ' .... y!fgi~ ••••• 
L HVG (rejection) I 
B. Single Response (bone marrow) 
.. 
D. Double response (bone marrow) 
Figure 5 Old (A and B) and new views (C and D) of transplantation recipients. A: the early 
conceptualization of immune mechanisms in organ transplantation in terms of a unidirectional host-
versus-graft (HVG) response. Although this readily explained organ rejection, it limited possible 
explanations of organ engraftment. B: mirror image of panel A depicting the early understanding of 
successful bone marrow transplantation as a complete replacement of the recipient immune system 
by that of the donor, with the potential complication of an unopposed lethal unidirectional graft-
versus-host (GVH) response: i.e. rejection of the recipient by the graft. C: our current view of bidi-
rectional and reciprocally modulating immune responses of coexisting immune competent cell 
populations. Because of variable reciprocal induction of deletional tolerance, organ engraftment was 
feasible despite a usually dominant HVG reaction. The bone silhouette in the graft represents passen-
ger leucocytes of bone marrow origin. D: Our currently conceived mirror image of panel C after suc-
cessful bone-marrow transplantation. Recipient's cytoablation has caused a reversal of the size 
proportions of the donor and recipient populations of immune cells 
(the upright curve in Figure 6) coincided with the characteristic reversal of rejec-
tion and induction of variable partial tolerance first observed 30 years earlier in 
our Colorado kidney recipients and eventually in all other kinds of organ recipi-
ent. Pretransplant cytoablation of the bone-marrow recipient simply reversed the 
proportions of the donor and recipient cells, transferring immune dominance to 
the graft (Figure 6, the inverted curve), thus explaining all of the differences 
between bone marrow and organ transplantation. 
What was not apparent in 1992, however, was how the microchimeric donor 
cells managed to survive in the organ recipient and why, as we had concluded, 
their persistence was essential for the long-term survival of a transplanted organ. 
Answers to these and other qnestions were provided 5 years later in a review 
written in collaboration with Rolf ZinkemageJ of Zurich56. In 1996 and 1997 
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Failure 
Immune f~~ ____________ ~~~;D;D~~~~~~~~~:== Reaction I" Success 
" . 
•••••••••• ~ Failure 
Time after Organ Transplantation 
Figure 6 Contemporaneous host-versus-graft (HVG) (upright curves) and graft-versus-host (OVH) 
(inverted curves) responses following organ transplantation. If some degree of reciprocal clonal 
exhaustion is not induced and maintained (usually requiring protective immune suppression), one 
cell population will destroy the other. In contrast to the usually dominant HVO reaction of organ 
transplantation (shown here), the GVH reaction is usually dominant in the cytoablated bone-marrow 
recipient. Therapeutic failure with either type of transplantation implies the inability to control one, 
the other, or both of the responses 
Zinkernagel and co-workers had concluded that the adaptive immune response 
and clinical course after infections by viruses and other non-cytopathic microor-
ganisms were determined primarily by the migration patterns of the pathogen57-60. 
This matched our conclusion that passenger leucocyte migration and relocation 
were the key events leading to organ engraftment or alternatively to rejection. 
Except for the different antigens of interest, we were independently describing the 
same phenomena. 
The role of the residual microchimerism in maintaining the clonal exhaustion-
deletion, induced at the outset by the flood of passenger leucocytes, was analo-
gous to that of persisting non-cytopathic microorganisms in perpetuating the 
carrier state following a systemic infection (e.g. by the hepatitis virus). This was 
only a detail, however, in the concept of immune regulation that we advanced 
which put transplantation and infection on common ground and was applicable in 
all other circumstances, including tumour surveillance and self-non-self discrimi-
nation. In essence immune responsiveness or non-responsiveness to a given anti-
gen is governed by the migration and localization of that antigen56. 
In this context organ engraftment was by definition a state of variable partial 
tolerance. Only two mechanisms of immune non-reactivity were necessary: 
clonal exhaustion-deletion and immune ignorance. Other previously postulated 
mechanisms of organ engraftment were not essential, singly or in combination. 
The role of immunosuppression in transplantation was not simply to eliminate 
the immune response, but rather to reduce it into a deletable range. In a second 
review we suggested how this tolerance could be made more complete with a 
different strategy of immunosuppression different from the one in general use6J • 
Adherence to two simple therapeutic principles would be required (Figure 7 A); 
the first was recipient pretreatment. The purpose was to reduce the anti-donor 
response by decreasing global responsiveness before arrival of the alloantigen. 
The second principle (minimal post-transplant immunosuppression) would 
require a profoundly counterintuitive departure from conventional practice. Here, 
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the objective was to give just enough post-transplant treatment to prevent irre-
f versible immune damage to the organ allograft, but not so much that the seminal 
i mechanism of clonal exhaustion-deletion would be precluded. 
The essential point of the second principle was that immunosuppression after 
transplantation is a two-edged sword. Over-treatment after transplantation can 
inhibit clonal activation so completely that the derivative event of clonal exhaus-
tion and deletion cannot occur, leaving the patient permanently dependent on 
high-dose maintenance immunosuppression (Figure 7B). In this view the world-
wide practice of starting heavy multidrug immunosuppression on the day of 
transplantation (so-called induction therapy) systematically closed the window 
of opportunity for tolerogenesis. It was a treatment policy that had been passed 
on from generation to generation for the past 40 years. 
This practice was introduced after compilation of the cluster of highly tolerant 
Colorado kidney recipients of phase I who have now carried their grafts for 40 
years. These pioneer early patients had been managed in accordance with both 
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Figure 8 Course of the recipient. in August 2001, of a cadaveric kidney following pretreatment 
with 5 mg/kg ALG a few hours before transplantation. Biopsy-proven rejection in the third week was 
treated with infusions of 1.0 g and 0.5 g prednisone. Daily tacrolimus (fully shaded area) was begun 
on the day after operation. Spacing of tacrolimus was begun after 7 months. Now, 21 years post-
transplantation, treatment has been with one dose per week for almost 2 years . 
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principles: pretreatment with Imuran, and the addition of no other drug after-
wards except for prednisone, and then only to treat rejection. In December 1963 
the pretreatment was de-emphasized because of preoperative infections. In sub-
sequent cases multidrug prophylactic immunosuppression was begun on the day 
of operation because of graft losses to non-reversible rejection. Without insight 
regarding engraftment mechanisms, this antitolerogenic use of immunosuppres-
sion became the worldwide state of the art. 
With the new insight, and armed with the better drugs available today, we now 
returned full cycle in July 2001 to phase 162,63, Pretreatment was given with an 
ALG (thymoglobulin®) similar to the one we introduced in 1966, or with a 
broadly reacting monoclonal antibody (Campath@). Minimum post-transplant 
monotherapy was given with tacrolimus (Figure 8) to which other agents were 
added only in the event of breakthrough rejection, In the patient whose course is 
shown in Figure 8, a bolus of prednisone was given in response to an early 
biopsy-proved kidney rejection. After approximately 4 months, weaning was 
begun from tacrolimus monotherapy by progressive spacing of doses to: every 
other day, three times a week, twice a week, and in many cases to one dose a 
week. The depicted patient has been on one dose a week tacrolimus for the past 
18 months. 
The strategy has been used for the treatment of more than 1000 kidney, liver, 
intestine, pancreas, and lung recipients. The patterns of treatment and convales-
cence were the same for all kinds of organ recipients. The quality of life achiev-
able with such treatment exceeds anything ever systematically achieved before. 
Thus, we are in the waning days of phase 4 in respect to both the controversy 
concerning the immunological mechanisms of tolerance and their facilitation by 
the revised use of immunosuppression. 
PHASE 5 
The same mechanisms and treatment principles are expected to apply for the 
transplantation of animal organs into humans (xenotransplantation). The recent 
elimination of the aGal epitope from pig tissues by knockout of the aI, 
3-galactosyltransferase gene64 has been an important step. Thus, phase 5 of the 
50-year war may already have begun. It is clear, however, that more genetic 
modifications are needed. It also is obvious that, if and when xenotransplantation 
is accomplished with pig donors, the engraftment mechanisms and therapeutic 
principles almost certainly will be the same as those of allotransplantation. The 
crucial migratory antigen will be the transgenic pig leucocyte. Even if the 
immune barrier is surmounted, it is not known whether the numerous metabolic 
products of the liver will be compatible with the human environment. 
POSTSCRIPT 
That concludes my chapter, except for a final comment. A third of a century ago 
(1970), I was invited to this city to receive an important international prize from the 
Falk Foundation. The prize was given for accomplishment of the first successful 
386 
CONNECTED PAST AND FUTURE OF TRANSPLANTATION 
human liver transplantations. Those few autumn days in Germany were a magical 
interlude in my life that I have cherished ever since. Many things have changed in 
the ensuing third of a century but, as a constant, the Falk Foundation has continu-
ously supported world hepatology. Thank you for inviting me to this Symposium. 
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